Thursday, July 7, 2022

Fonterra Summary of Key Announcements on Quality Issue

Fonterra has advised regulatory authorities and customers of a quality issue involving three batches of Fonterra whey protein concentrate (WPC80) produced at the Hautapu manufacturing site in New Zealand. The affected product potentially contained a strain of Clostridium, which has the potential to cause botulism and we decided to take a precautionary approach. There have been no confirmed reports of any illness linked to consumption of the affected whey protein. However, food safety is Fonterra’s number one priority and the Co-operative takes matters of public health extremely seriously. We are doing everything we can to assist our eight impacted customers to take appropriate actions in the consumer marketplace. On Saturday afternoon we confirmed that no Fonterra-branded consumer products are affected by the quality issue. We assured consumers in global markets including Australia, Asia, China, Latin America, New Zealand and the Middle East that none of our range of branded consumer products contained the affected WPC80. The three specific batches of WPC80 produced at Hautapu, are the only NZMP ingredients affected by this quality issue. These batches were sold to eight of Fonterra’s customers – with some receiving it as base product and others receiving finished product manufactured by Fonterra using the affected WPC80 as an ingredient. Of these customers, three are food companies, two are beverage companies and three are companies that manufacture animal stock feed. Prior to the market opening on Monday 5 August 2013 we updated the market on developments over the weekend and on that afternoon we hosted another media conference. Theo Spierings was in China to meet with Chinese government officials, regulators and customers, and held a media conference there. We received confirmati

Total
0
Shares
More articles on this topic